| Schedule of Marketable Securities Include Investments in Equity Securities |
The Company’s marketable securities
include investments in equity securities of IC Hotels (“DNA”), Entera Bio Ltd.
| | |
March 31,
2026 | | |
December 31,
2025 | |
| Short -term: | |
| | |
| |
| DNA | |
$ | 466 | | |
$ | 540 | |
| Entera | |
| 130 | | |
| 227 | |
| Pelthos (*) | |
| 3,013 | | |
| 4,650 | |
| Nano’s Put options and written Call options, net (**) | |
| 1,356 | | |
| - | |
| | |
$ | 4,965 | | |
$ | 5,417 | |
| | |
March 31,
2026 | |
| | |
March 31,
2026 | | |
December 31,
2025 | |
| Long-term: | |
| | |
| |
| Nano (***) | |
| 17,967 | | |
| 8,371 | |
| | |
$ | 17,967 | | |
| 8,371 | |
| (*) | During the three months ended March 31, 2026, the Company sold
6,577 shares of Pelthos common stock for aggregate proceeds of $173, resulting in a realized gain of $107 recognized in “financial
income (loss), net” in the consolidated statement of comprehensive income (loss). |
| (**) | The written call options and put options on Nano’s shares are held with the same counterparty and are subject to a netting arrangement. Accordingly, they are presented on a net basis in the consolidated balance sheets. As of March 31, 2026, the fair values of written call options and put options were $402 and $1,758, respectively. See Note 18 for further details. |
| (***) | During the three months ended March 31, 2026, the Company purchased
6,401,939 ordinary shares for an aggregate purchase price of $12,258 and sold 1,269,987 shares of Nano common stock for aggregate proceeds
of $2,606, resulting in a realized gain of $647 recognized in “financial income (loss), net” in the consolidated statement
of comprehensive income (loss). See Note 18 for further details. |
|